Pricing Log in Create free account
Friday 6 November 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.

Revenue
+10.4%
EPS
−280.5%
Free cash flow
−60.4%
Total debt
+3.88%

Quarter to September 2026, against a year earlier

235.34 8.02 +3.53%
Market cap
$14.6B
P/E
62.6×
Fwd P/E
35.9×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Jazz Pharmaceuticals PLC 8-K filed Oct 22, 2025

Period ended Oct 21, 2025 · Filed · accepted 9:01 AM ET · Document on sec.gov · Filing index

8.01 Other events

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov